Is GUBamy legal in Australia?

A long-acting amylin analogue from Gubra with one completed phase 1 trial of 76 people sponsored by AbbVie. No result from that trial, and no other human or animal data, has been published; PubMed holds zero records for the compound. Weight loss figures circulating for it could not be traced to any primary source.

GUB014295, referred to as GUBamy in its originator's communications, is a long-acting analogue of amylin, the pancreatic hormone co-secreted with insulin that slows gastric emptying, suppresses glucagon and promotes satiety. It was discovered by the Danish company Gubra.

Mechanism: Amylin acts on receptors formed by the calcitonin receptor paired with receptor activity modifying proteins, in the hindbrain area postrema and elsewhere, to slow gastric emptying, suppress post-meal glucagon secretion and reduce food intake by promoting meal termination. Native amylin aggregates and lasts minutes; long-acting analogues are engineered to resist aggregation and to bind albumin or carry a lipid chain so that they can be dosed weekly.

Regulatory history: Not approved. One completed phase 1 (NCT06144684, 76 participants, sponsor AbbVie) with safety primary outcomes; no results posted, no publications.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for GUBamy at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.